Head to Head Comparison: ASP Isotopes (NASDAQ:ASPI) versus Westaim (OTCMKTS:WEDXF)

ASP Isotopes (NASDAQ:ASPI) and Westaim (OTCMKTS:WEDXF) are both small-cap materials companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares ASP Isotopes and Westaim”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASP Isotopes	$23.85 million	24.94	-$175.09 million	($1.32)	-2.94
Westaim	$53.37 million	8.78	-$38.00 million	($4.36)	-3.23

Westaim has higher revenue and earnings than ASP Isotopes. Westaim is trading at a lower price-to-earnings ratio than ASP Isotopes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ASP Isotopes and Westaim’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ASP Isotopes	-427.98%	-64.99%	-32.20%
Westaim	-232.90%	-22.31%	-17.52%

Volatility & Risk

ASP Isotopes has a beta of 3.61, indicating that its share price is 261% more volatile than the S&P 500. Comparatively, Westaim has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.

Institutional & Insider Ownership

16.8% of ASP Isotopes shares are held by institutional investors. 14.4% of ASP Isotopes shares are held by insiders. Comparatively, 4.2% of Westaim shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for ASP Isotopes and Westaim, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASP Isotopes	1	0	2	0	2.33
Westaim	0	0	0	0	0.00

ASP Isotopes presently has a consensus price target of $13.00, indicating a potential upside of 235.05%. Given ASP Isotopes’ stronger consensus rating and higher possible upside, analysts clearly believe ASP Isotopes is more favorable than Westaim.

Summary

ASP Isotopes beats Westaim on 9 of the 14 factors compared between the two stocks.

About ASP Isotopes

ASP Isotopes Inc., a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc. was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

About Westaim

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.